Clinical Evaluation of Branched DNA Signal Amplification for Quantifying HIV Type 1 in Human Plasma

AIDS Research and Human Retroviruses

Volumn 11, Issue 3, 1995, Pages 353-361

  Cao, Yunzhen ^a   ho, David D ^a   Todd, John ^b   Kokka, Robert ^b   Urdea, Mickey ^b   Lifson, Jeffrey D ^c   Piatak, Michael ^c   Chen, Shande ^d   Hahn, Beatrice H ^d   Saag, Michael S ^d   Shaw, George M ^d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Genelabs Incorporated   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN P24; CD4 ANTIGEN; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ANTIBODY DETECTION; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME IMMUNOASSAY; GENE AMPLIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SEROCONVERSION; VIRUS CONCENTRATION; VIRUS DETECTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DNA; HIV CORE PROTEIN P24; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; TIME FACTORS; ZIDOVUDINE;

EID: 0028986503     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.1995.11.353     Document Type: Article

References (60)

1. Ho DD, Moudgil T, and Alam M: Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl JMed 1989;321:1621-1625.
2. Coombs RW, Collier AC, Allain J-P, et ai: Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321:1626-1631.
3. Saag MS, Crain MJ, Decker WD, et ai: High level viremia in adults and children infected with human immunodeficiency virus: Relation to disease stage and CD4+ lymphocyte levels. J Infect Dis 1991;164:72-80.
4. Wei X, Ghosh SK, Taylor ME, et ai: Viral dynamics in HIV-1 infection. Nature 1995;373:117-122.
5. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz, M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
6. Michael NL, Vahey M, Burke DS, and Redfield RR: Viral DNA and mRNA expression correlate with the stage of human immunodeficiency virus (HIV) type 1 infection in humans: Evidence for viral replication in all stages of HIV disease. J Virol 1992; 66:310-316.
7. Pantaleo G, Graziosi C, Demarest JF, et ai: HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature (London) 1993;362:355-358.
8. Embretson J, Zupancic M, Ribas JL, et ai: Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature (London) 1993;362:359-362.
9. Piatak M Jr. Saag MS, Yang LC, et ai: High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 1993;259:1749-1754.
10. Winters MA, Tan LB, Katzenstein DA, and Merigan TC: Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J Clin Microbiol 1993;31:2960-2966.
11. Pantaleo G, Graziosi C, Butini L, et ai: Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci USA 1991;88:9838-9842.
12. Connor RI, Mohri H, Cao Y, and Ho DD: Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1 infected individuals. J Virol 1993;67:1772-1777.
13. Clark SJ, Saag MS, Decker WD, et ai: High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-960.
14. Daar ES, Mougdil T, Meyer RD, and Ho DD: Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med 1991;324:961-964.
15. Allain JP, Laurian Y, Paul DA. et ai: Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. NEnglJMed 1987;317:1114-1121.
16. Eyster ME, Ballard JO, Gail MH, Drummond JE, and Goedert JJ: Predictive markers for the acquired immunodeficiency syndrome (AIDS) in hemophiliacs: Persistence of p24 antigen and low T4 cell count. Ann Int Med 1989;110:963-969.
17. Hammer S, Crumpacker C, D'Aquila R, et ai: Use of virologie assays for detection of human immunodeficiency virus in clinical trials: Recommendations of the AIDS Clinical Trials Group Virology Committee. J Clin Microbiol 1993;31:2557-2564.
18. DeGruttola V, Beckett LA, Coombs RW, et ai: Serum p24 antigen level as an intermediate end point in clinical trials of zidovudine in people infected with human immunodeficiency virus type 1. J Infect Dis 1994;169:713-721.
19. Nishanian P, Huskins KR, Stehn S, Detels R, and Fahey JL: A simple method for improved assay demonstrates that HIV p24 antigen is present as immune complexes in most sera from HIV-infected individuals. J Infect Dis 1990;162:21-28.
20. Bollinger RC, Kline RL, Francis HL. Moss MW, Bartlett JG, and Quinn TC: Acid dissociation increases the sensitivity of p24 antigen detection for the evaluation of antiviral therapy and disease progression in asymptomatic human immunodeficiency virus-infected persons. J Infect Dis 1992;165:913-916.
21. Jackson GG, Paul DA, Falk LA, et ai: Human immunodeficiency virus (HIV) antigenemia (p24) in the acquired immunodeficiency syndrome (AIDS) and the effect of treatment with zidovudine (AZT). Ann Intern Med 1988;108:175-180.
22. Chaisson RE, Leuther MD, Allain JP, et al.: Effect of zidovudine on serum human immunodeficiency virus core antigen levels. Results from a placebo-controlled trial. Arch Intern Med 1988;148:2151-2153.
23. Yerly S, Chamot E, Hirschel B, and Perrin LH: Quantitation of human immunodeficiency provirus and circulating virus: Relationship with immunologic parameters. J Infect Dis 1992;166:269-276.
24. Molecular profile of human immunodeficiency virus type 1 infection in symptomless patients and in patients with AIDS, P., Bagnarelli, S., Menzo, A., Valenza, et al., J Virol, (1992), 66, 7328-7335
25. Bagnarelli P, Valenza A, Menzo S, et al: Dynamics of molecular parameters of human immunodeficiency virus type 1 activity in vivo. J Virol 1994;68:2495-2502.
26. Furtado MR, Murphy R, and Wolinsky SM: Quantification of human immunodeficiency virus type 1 tat mRNA as a marker for assessing the efficacy of antiretroviral therapy. J Infect Dis 1993;167:213-216.
27. Saksela K, Stevens C, Rubinstein P, and Baltimore D: Human immunodeficiency virus type 1 mRNA expression in peripheral blood cells predicts disease progression independently of the numbers of CD4+ lymphocytes. Proc Natl Acad Sci USA 1994;91:1104-1108.
28. Freitas AA and Rocha BB: Lymphocyte lifespans: Homeostasis, selection and competition. Immunol Today 1993;14:25-29.
29. Saksela K, Muchmore E, Girard M, Fultz P, and Baltimore D: High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1 infected chimpanzees. J Virol 1993;67:7423-7427.
30. Bagasra O, Hauptman SP, Lischner HW, Sachs M, and Pomerantz RJ: Detection of human immunodeficiency virus type 1 provirus in mononuclear cells by in situ polymerase chain reaction. N Engl J Med 1992;326:1385-1391.
31. Patterson BK, Till M, Otto P, et al: Detection of HIV-1 DNA and messenger RNA in individual cells by PCR-driven in situ hybridization and flow cytometry. Science 1993;260:976-979.
32. Meyerhans A, Cheynier R, Albert J, et al: Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989;58:901-910.
33. Li Y, Hui H, Burgess CJ, et al: Complete nucleotide sequence, genome organization, and biological properties of human immunodeficiency virus type 1 in vivo: Evidence for limited defectiveness and complementation. J Virol 1992;66:6587-6600.
34. Walker CM, Moody DJ, Stites DP, and Levy JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986;234:1563-1566.
35. Walker CM and Levy JA: A diffusible lymphokine produced by CD8+ T lymphocytes suppresses HTV replication. Immunology 1989;66:628-630.
36. Moore JP, Cao Y, Ho DD, and Koup RA: Development of the anti-gpl20 antibody response during seroconversion to human immunodeficiency virus type I. J Virol 1994;68:5142-5155.
37. Layne SP, Merges MJ, Dembo M, et al: Factors underlying spontaneous inactivation and susceptibility to neutralization of human immunodeficiency virus. Virology 1992;189:695-714.
38. McKeating JA and Moore JP: HIV infectivity. Nature (London) 1991;349:660.
39. Aoki-Sei S, Yarchoan R, Kageyama S, et al: Plasma HIV-1 viremia in HFV-1 infected individuals assessed by polymerase chain reaction. AIDS Res Hum Retroviruses 1992;8:1263-1270.
40. Lin HJ, Myers LE, Yen-Leiberman B, et al: Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA. J Infect Dis 1994;170:553-562.
41. Holodniy M, Katzenstein DA, Sengupta S, et al: Detection and quantification of human immunodeficiency virus RNA in patient serum by use of the polymerase chain reaction. J Infect Dis 1991;163:862-866.
42. Holodniy M, Katzenstein DA, Israelski DM, and Merigan TC: Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J Clin Invest 1991;88:1755-1759.
43. Holodniy M, Katzenstein DA, Winters M, et al: Measurement of HIV virus load and genotypic resistance by gene amplification in asymptomatic subjects treated with combination therapy. J AIDS 1993,6:366-369.
44. Katzenstein DA, Winters M, Bubp J, Israelski D, Winger E, and Merigan TC: Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine. J Infect Dis 1994; 169:416-419.
45. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, and Kwok S: Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J Clin Microbiol 1994;32:292-300.
46. Pachl C, Todd JA, Kern DG, et al: Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA (bDNA) signal amplification assay. J AIDS 1995 (in press).
47. Coombs RW, Henrard DR, Mehaffey WF, et al: Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction. J Clin Microbiol 1993;31:1980-1986.
48. van Gemen B, Kievits T, Nara P, et al: Qualitative and quantitative detection of HIV-1 RNA by nucleic acid sequence-based amplification. AIDS 1993;7(S2):S107-S110.
49. Jurriaans S, van Gemen B, Weverling GJ, et al: The natural history of HIV-1 infection: Virus load and virus phenotype independent determinants of clinical course. Virology 1994;204:223-233.
50. Urdea MS: Synthesis and characterization of branched DNA (bDNA) for the direct and quantitative detection of CMV, HBV, HCV, and HIV. Clin Chem 1993;39:725-726.
51. Henrard DR, Mehaffey WF, and Allain J-P: A sensitive viral capture assay for detection of plasma viremia in HIV-infected individuals. HIV Res Hum Retroviruses 1992;8:47-52.
52. Scadden DT, Wang Z, and Groopman JE: Quantitation of plasma human immunodeficiency virus type 1 RNA by competitive polymerase chain reaction. J Infect Dis 1992;165:1119-1123.
53. Saag MS, Emini EA, Laskin OL, et al: A short-term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase. N Engl J Med 1993;329:1065-1072.
54. Kappes JC, Saag MS, Shaw GM, et al: Assessment of antiretroviral therapy by plasma viral load testing: Standard and ICD HIV-1 p24 antigen and viral RNA (QC-PCR) assays compared. J AIDS 1995 (in press).
55. Conover WJ: Practical Nonparametric Statistics, 2nd ed. John Wiley & Sons, New York, 1980.
56. SAS/STAT User's Guide, version 6, SAS/STAT User's Guide, version 6, 4th ed. SAS Institute, Cary, North Carolina, (1990)
57. Piatak M, Yang LC, Luk KC, et al: Viral dynamics in primary HIV-1 infection. Lancet 1993;341:1099.
58. Dewar RL, Highbarger HC, Sarmiento MD, et al: Application of branched DNA (bDNA) signal amplification to monitor HIV-1 burden in human plasma. J Infect Dis 1994;170:1172-1179.
59. Cohen J: Searching for markers on the AIDS trail. Science 1992;258:388-390.
60. Lagakos SW: Surrogate markers in AIDS clinical trials: Conceptual basis, validation, and uncertainties. Clin Infect Dis 1993;16(Suppl. 1):S22-S25.